BOM:524743 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BOM:524743 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Fischer Medical Ventures Ltd BOM:524743
Fischer Medical Ventures BOM:524743 -1.96% 40 EBIT is ₹522 Mil as of Mar. 2026. GuruFocus rates BOM:524743 with a GF Score™ of 40/100 and a GF Value™ of ₹217.73 (Possible Value Trap). The stock has 3 warning signs investors should review.
Fischer Medical Ventures's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹13 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹522 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fischer Medical Ventures's annualized ROC % for the quarter that ended in Mar. 2026 was 0.06%. Fischer Medical Ventures's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.26%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fischer Medical Ventures's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.89%.
Fischer Medical Ventures (BOM:524743) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Fischer Medical Ventures's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:
| ROC % (Q: Mar. 2026 ) | ||||||
| = | NOPAT | / | Average Invested Capital | |||
| = | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Dec. 2025 ) | + | Invested Capital (Q: Mar. 2026 )) | / count ) |
| = | 3.092 * ( 1 - 0% ) | / | ( (0 | + | 5193.532) | / 1 ) |
| = | 3.092 | / | 5193.532 | |||
| = | 0.06 % |
where
| Invested Capital | (Q: Dec. 2025 ) | |||||||||||
| = | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
| = | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
| = | 0 | - | 0 | - | ( 0 | - | max(0, 0 | - | 0 | + | 0 | )) |
| = | 0 |
| Invested Capital | (Q: Mar. 2026 ) | |||||||||||
| = | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
| = | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
| = | 6710.106 | - | 1201.083 | - | ( 315.491 | - | max(0, 2580.257 | - | 4175.872 | + | 315.491 | )) |
| = | 5193.532 |
Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.
2. Joel Greenblatt's definition of Return on Capital:
Fischer Medical Ventures's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:
| ROC (Joel Greenblatt) % | (Q: Mar. 2026 ) | ||||||
| = | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
| = | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
| Q: Dec. 2025 | Q: Mar. 2026 | ||||||
| = | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
| = | 53.776 | / | ( ( (0 + max(0, 0)) | + | (293.294 + max(2082.327, 0)) ) | / | 1 ) |
| = | 53.776 | / | ( ( 0 | + | 2375.621 ) | / | 1 ) |
| = | 53.776 | / | 2375.621 | ||||
| = | 2.26 % |
where Working Capital is:
| Working Capital | (Q: Dec. 2025 ) | ||||||||||
| = | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
| = | (0 | + | 0 | + | 0) | - | (0 | + | 0 | + | 0) |
| = | 0 |
| Working Capital | (Q: Mar. 2026 ) | ||||||||||
| = | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
| = | (2887.98 | + | 126.632 | + | 845.769) | - | (1201.083 | + | 0 | + | 576.971) |
| = | 2082.327 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Fischer Medical Ventures's Earnings Yield (Joel Greenblatt) % for today is calculated as:
| Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Mar. 2026 ) |
| = | 521.959 | / | 27571.788 | |
| = | 1.89 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The historical data trend for Fischer Medical Ventures's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Fischer Medical Ventures Annual Data | |||||||||||||||||||||
| Trend | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | Mar25 | Mar26 | |||||||||||
| EBIT | Get a 7-Day Free Trial |
|
|
-1.89 | 0.15 | 21.79 | 26.90 | 521.96 | |||||||||||||
| Fischer Medical Ventures Quarterly Data | ||||||||||||||||||||
| Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | |
| EBIT | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
20.39 | 108.45 | 181.81 | 218.26 | 13.44 | ||
For the Medical Devices subindustry, Fischer Medical Ventures's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Fischer Medical Ventures's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fischer Medical Ventures's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹522 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Based on GuruFocus' analysis, Fischer Medical Ventures stock appears to be undervalued. The current stock price of ₹40.96 is trading 81.2% below its estimated GF Value™ of ₹217.73. GuruFocus considers Fischer Medical Ventures to be Possible Value Trap.
Key valuation signals for BOM:524743:
No single metric tells the full story. See the BOM:524743 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.